Loading…
BuyNetMeds.com, an India-based online pharmacy, was cited for unlawfully selling unapproved and misbranded drugs to U.S. consumers via the internet, violating sections 301(a), 301(d), 301(k), 503(b), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The company specifically offered unapproved opioid products and injectable semaglutide products without FDA approval or proper labeling, posing serious risks including contamination, counterfeit formulations, inconsistent active ingredient amounts, and life-threatening conditions from injectable drug use. Given the ongoing opioid epidemic and the particular dangers of unregulated injectable medications, FDA demanded the company immediately cease sales of all unapproved and misbranded drugs to U.S. consumers.